Vanguard Personalized Indexing Management LLC Decreases Stake in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Vanguard Personalized Indexing Management LLC has reduced its stake in Jazz Pharmaceuticals PLC by 55.1%, leaving it with 4,005 shares valued at approximately $425,000.
• Several institutional investors, including Goldman Sachs Group Inc. and Nuveen LLC, have recently increased their holdings in Jazz Pharmaceuticals, highlighting strong interest in the company.
• Analysts are generally positive, with a consensus rating of "Moderate Buy" and an average target price of $179.80, following recent price target increases from firms like Truist Financial and Morgan Stanley.

Vanguard Personalized Indexing Management LLC lessened its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 55.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,005 shares of the specialty pharmaceutical company's stock after selling 4,919 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in Jazz Pharmaceuticals were worth $425,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JAZZ. Nuveen LLC bought a new position in shares of Jazz Pharmaceuticals in the first quarter valued at $62,362,000. Fuller & Thaler Asset Management Inc. grew its position in shares of Jazz Pharmaceuticals by 41.7% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock valued at $165,245,000 after purchasing an additional 391,660 shares during the last quarter. Perpetual Ltd lifted its stake in shares of Jazz Pharmaceuticals by 60.2% in the first quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock valued at $118,212,000 after buying an additional 357,784 shares during the period. Dimensional Fund Advisors LP raised its position in Jazz Pharmaceuticals by 14.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company's stock worth $289,066,000 after purchasing an additional 293,360 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in Jazz Pharmaceuticals by 147.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company's stock worth $43,652,000 after buying an additional 209,667 shares in the last quarter. Institutional investors own 89.14% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on JAZZ. Truist Financial boosted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. Morgan Stanley raised their price target on shares of Jazz Pharmaceuticals from $167.00 to $180.00 and gave the stock an "overweight" rating in a report on Monday. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target on the stock. Wells Fargo & Company set a $170.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday. Finally, The Goldman Sachs Group boosted their price objective on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a research note on Friday, August 29th. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $179.80.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 3,500 shares of the firm's stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $140.00, for a total value of $490,000.00. Following the transaction, the director owned 408,826 shares in the company, valued at approximately $57,235,640. This trade represents a 0.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders have sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is owned by company insiders.

Jazz Pharmaceuticals Trading Up 0.7%

Shares of JAZZ opened at $138.52 on Thursday. The company has a 50 day simple moving average of $129.60 and a two-hundred day simple moving average of $116.44. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The firm has a market cap of $8.40 billion, a P/E ratio of -20.58, a price-to-earnings-growth ratio of 8.44 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The company had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.